Acadia Pharmaceuticals Reports Strong Q1 Revenue Growth, Reaffirms 2026 Guidance
ACAD sits 51% above its 52-week low of $14.45 on elevated volume (1.9× avg).
Summary
Acadia Pharmaceuticals announced its first quarter 2026 financial results, reporting significant revenue growth for its key products DAYBUE and NUPLAZID, while reaffirming its full-year 2026 financial guidance.
Key Events · Earnings and Guidance · ACAD
-
Strong Q1 Revenue Growth
Total revenues increased 10% year-over-year to $268 million for the first quarter of 2026.
-
Key Product Sales Performance
DAYBUE net sales rose 20% to $101 million, with NUPLAZID net sales increasing 5% to $167 million. The launch of DAYBUE STIX is progressing well.
-
Full-Year Guidance Reaffirmed
The company reiterated its 2026 financial guidance, indicating that Q1 results align with its annual projections.
-
Increased SG&A Impacts Net Income
Net income for the quarter was $4 million, down from $19 million in Q1 2025, primarily due to higher selling, general, and administrative expenses supporting product growth.
Analysis · ACAD · Life Sciences
Acadia Pharmaceuticals reported a solid first quarter for 2026, with total revenues increasing 10% year-over-year to $268 million, driven by strong sales of DAYBUE and NUPLAZID. DAYBUE sales notably grew 20% to $101 million, supported by the successful launch of DAYBUE STIX. While net income decreased significantly to $4 million due to increased selling, general, and administrative expenses, these investments are aimed at supporting continued product growth. Crucially, the company reaffirmed its full-year 2026 financial guidance, signaling that performance is in line with management's expectations. Positive pipeline updates, including remlifanserin's Phase 2 results remaining on track and accelerated enrollment for trofinetide in Japan, further support the company's long-term outlook.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACAD was trading at $21.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $14.45 to $28.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.